The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.
Cancer Treat Rev
; 74: 29-34, 2019 Mar.
Article
em En
| MEDLINE
| ID: mdl-30708267
ABSTRACT
Patients with luminal early breast cancer are at risk of relapse, even after five years of adjuvant endocrine therapy. To date, no biomarkers have been clinically validated to identify those patients at risk of late recurrence, who might benefit from extended adjuvant endocrine therapy. In recent decades, multiple clinical trials have tested the role of extending adjuvant endocrine therapies in patients with luminal disease. However, the data currently at our disposal are conflicting. This article reviews all the major trials concerning extended adjuvant endocrine regimens, and formulates some general conclusions and hypotheses of future study.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Antineoplásicos Hormonais
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Cancer Treat Rev
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Suíça